Investors

News & Releases

October 8th, 2020

IPA Delivers Lead Candidate Antibodies from B Cell Select™ Platform for at Home SARS-CoV-2 Diagnostic Test

Also signs Definitive Commercial Agreement with University of Victoria VICTORIA, October 8, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2),…

October 6th, 2020

IPA’s CEO Dr. Jennifer Bath to Appear Live Wednesday on BNN Television

VICTORIA, October 6, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,…

October 5th, 2020

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

VICTORIA, October 05, 2020 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today…

September 29th, 2020

ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021

VICTORIA, September 29, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2021 first quarter ended…